Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Date

Click to order products descending

Display 15 Products per page

Fovista
Read More
Fovista (pegpleranib; Ophthotech/Novartis) is a PEGylated aptamer targeting platelet-derived growth factor (PDGF). The drug is designed to be used in combination with a vascular endothelial growth factor (VEGF) inhibitor.
April 7, 2016
Find out more
Macugen
Read More
Macugen (pegaptanib; Valeant/Pfizer) is a PEGylated oligonucleotide aptamer which binds selectively

to vascular endothelial growth factor (VEGF)-165, an isoform of VEGF found to induce angiogenesis

and increase vascular permeability (Natarajan, 2013).
April 7, 2016
Find out more
blisibimod
Read More
Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
April 5, 2016
Find out more
Visudyne
Read More
Visudyne (verteporfin; Valeant/Novartis) is a benzoporphyrin derivative photosensitizer developed for

use in photodynamic therapy.
April 4, 2016
Find out more
Herceptin
Read More
Herceptin is a humanized MAb targeting the HER2 receptor, a member of the human epidermal

growth factor receptor family.
March 22, 2016
Find out more
Reasanz
Read More
Reasanz (serelaxin; Novartis) has not yet obtained approval in the US, Japan, or EU for the treatment

of acute decompensated heart failure (ADHF), despite its fast track and breakthrough therapy

designations from the US Food and Drug Administration (FDA).
March 16, 2016
Find out more
Ularitide
Read More
Ularitide’s (Cardiorentis) favorable results in its pivotal Phase III trial could be a key driver of uptake,

especially as Natrecor (nesiritide; Johnson & Johnson), its major marketed competitor, failed to show

added clinical value and benefit on survival.
March 16, 2016
Find out more
Bax 817
Read More
BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…
March 14, 2016
Find out more
CSL627
Read More
CSL627 is a single-chain rfVIII product in development for hemophilia A. Endogenously produced fVIII consists of a light chain and a heavy chain fused via a metal ion bridge.
March 14, 2016
Find out more
Cometriq
Read More
Cometriq is an orally available small molecule inhibitor currently being developed by Exelixis as

second-line therapy for patients with relapsed or metastatic RCC.
February 5, 2016
Find out more
AGS-003
Read More
AGS-003 (Argos Therapeutics/Kyowa Hakko Kirin) is a cancer vaccine in development for the first-line treatment of metastatic renal cell cancer (RCC) in combination with Sutent (sunitinib; Pfizer).
February 5, 2016
Find out more
Entinostat
Read More
Entinostat is a class I selective histone deacetylase (HDAC) inhibitor. HDACs influence the expression of genes involved in both the initiation of cancer
February 5, 2016
Find out more
Taselisib
Read More
Taselisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in
tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Find out more
Alpelisib
Read More
Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Find out more
Ixempra
Read More
Ixempra (ixabepilone; R-Pharm/Otsuka) is a lactam analog of epothilone B that binds to microtubules via tubulin.
February 4, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *